Tham khảo Gabapentin_enacarbil

  1. ↑ Landmark CJ, Johannessen SI (2008). “Modifications of antiepileptic drugs for improved tolerability and efficacy”. Perspectives in Medicinal Chemistry. 2: 21–39. PMC 2746576. PMID 19787095.
  2. ↑ Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA (tháng 10 năm 2004). “XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters”. The Journal of Pharmacology and Experimental Therapeutics. 311 (1): 315–23. doi:10.1124/jpet.104.067934. PMID 15146028.
  3. ↑ Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA (tháng 10 năm 2004). “XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys”. The Journal of Pharmacology and Experimental Therapeutics. 311 (1): 324–33. doi:10.1124/jpet.104.067959. PMID 15146029.
  4. ↑ Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM (tháng 12 năm 2008). “Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin”. Journal of Clinical Pharmacology. 48 (12): 1378–88. doi:10.1177/0091270008322909. PMID 18827074.
  5. ↑ Lal R, Sukbuntherng J, Luo W, Huff FJ, Zou J, Cundy KC (tháng 2 năm 2010). “The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil”. International Journal of Clinical Pharmacology and Therapeutics. 48 (2): 120–8. doi:10.5414/cpp48120. PMID 20137764.
  6. ↑ Merlino G, Serafini A, Lorenzut S, Sommaro M, Gigli GL, Valente M (tháng 1 năm 2010). “Gabapentin enacarbil in restless legs syndrome”. Drugs of Today (Barcelona, Spain: 1998). 46 (1): 3–11. doi:10.1358/dot.2010.46.1.1424766. PMID 20200691.
  7. ↑ Bogan RK, Bornemann MA, Kushida CA, Trân PV, Barrett RW (tháng 6 năm 2010). “Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study”. Mayo Clinic Proceedings. 85 (6): 512–21. doi:10.4065/mcp.2009.0700. PMC 2878254. PMID 20511481.
  8. ↑ Imamura S, Kushida C (tháng 8 năm 2010). “Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome”. Expert Opinion on Pharmacotherapy. 11 (11): 1925–32. doi:10.1517/14656566.2010.494598. PMID 20629607.
  9. ↑ “GlaxoSmithKline/XenoPort: FDA setback halts gabapentin reformulations”. Bản gốc lưu trữ ngày 14 tháng 4 năm 2020. Truy cập ngày 17 tháng 6 năm 2019.
  10. ↑
  11. ↑ Jeffrey, Susan. “FDA Approves Gabapentin Enacarbil for Postherpetic Neuralgia”. Medscape.